Kenvue with a clear analyst picture, shares extend a strong June run
29.06.2026 - 15:11:59 | ad-hoc-news.de
By Anna Wagner, Analysts & Consensus desk. Reviewed prior to publication on 2026-06-29, 15:11.
Kenvue (US49177J1025) enters the new week with a well-documented analyst consensus and a marked share-price recovery on the NYSE. The stock stands in the consumer health peer group with Haleon and Perrigo as reference names, giving investors a clear sector context.
What the analyst consensus shows
Analyst data compiled by wallstreet-online indicates that around 16 percent of tracked analysts rate Kenvue shares as Strongbuy, 11 percent as Buy and roughly 74 percent as Hold, resulting in an average score of 3.42 out of 5 points. Analyst breakdown for Kenvue This distribution suggests a cautious but supportive stance, with most houses seeing limited downside but only moderate upside.
In that same data set, Kenvue’s rating profile is framed within the wider consumer staples universe, where companies such as Haleon and Perrigo also attract predominantly Hold recommendations, underlining the sector’s defensive but valuation-sensitive character. MarketBeat overview of Kenvue For retail investors, this mix of Hold and selective Buy calls provides a concrete picture of how the stock is currently viewed on Wall Street.
Performance data and sector backdrop
According to real-time indications on wallstreet-online, Kenvue shares show a gain of about 13.88 percent for the current month and a year-to-date performance around 14.54 percent, with the stock trading roughly 40 percent above its 52-week low and about 14.6 percent below its 52-week high. Performance metrics for Kenvue Over the last 30 days, the shares are up approximately 11.18 percent, pointing to a robust June rally.
MarketBeat pegs Kenvue’s latest regular NYSE close around 19.14 US dollars on June 26, 2026, with extended-hours trading showing prints in the high 18-dollar range. NYSE quote summary for KVUE That positions Kenvue among consumer health peers whose valuations reflect both stable cash flows and sensitivity to interest-rate expectations and defensive sector rotations.
All news and analysis on the Kenvue shares
Further company reports, price updates and regulatory disclosures on Kenvue are collected in the dedicated topic section and on the group’s Investor Relations page.
The brands behind Kenvue
Kenvue operates as a global consumer health company with three primary segments: Self Care, Skin Health and Beauty, and Essential Health, offering over-the-counter medicines and personal-care products across North America, Europe, Asia-Pacific, Latin America, the Middle East and Africa. Business description for Kenvue Representative brands include Tylenol for pain management, Zyrtec for allergy relief and Nicorette for smoking cessation support.
Where the shares trade today
The Kenvue shares (US49177J1025) trade on the NYSE under the ticker KVUE and recently closed around 19.14 US dollars on 2026-06-26, 15:59 Eastern Time, based on MarketBeat price data. Latest NYSE closing price for KVUE
Key data on the Kenvue shares
- Company: Kenvue Inc.
- ISIN: US49177J1025
- WKN: A3EEHU
- Ticker: KVUE
- Trading venue: NYSE
- Price (as of 2026-06-26, 15:59): 19.14 USD
- Market cap: approximately 36 billion USD (as of late June 2026, based on NYSE data)
- Sector / industry: Consumer Staples / Consumer Health
- Index membership: not included in the S&P 500 or NASDAQ-100 at the time of writing
- Next earnings date: not officially scheduled
This article is for informational purposes only and does not contain any investment advice, buy or sell recommendations, or personal financial guidance. All data and assessments are based on sources cited in the text and may change over time.
